Evidence map›Paper›PMID 37352154›Full record

ArticleAlimentary pharmacology & therapeutics2023

Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary.

Péter Bacsur, Ákos Iliás, Tamás Resál, Diána Kata, Tamás Molnár, Klaudia Farkas

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Péter BacsurDepartment of Medicine, Szent-Györgyi Albert Medical School, University of Szeged, Szeged, Hungary.ORCID 0000-0002-8534-0068
Ákos IliásDepartment of Medicine and Oncology, Semmelweis University, Budapest, Hungary.
Tamás ResálDepartment of Medicine, Szent-Györgyi Albert Medical School, University of Szeged, Szeged, Hungary.ORCID 0000-0002-3842-9094
Diána KataDepartment of Laboratory Medicine, University of Szeged, Szeged, Hungary.
Tamás MolnárDepartment of Medicine, Szent-Györgyi Albert Medical School, University of Szeged, Szeged, Hungary.ORCID 0000-0002-4913-7599
Klaudia FarkasDepartment of Medicine, Szent-Györgyi Albert Medical School, University of Szeged, Szeged, Hungary.

Funding

Faculty of Medicine, University of SzegedGéza Hetényi Research GrantJanos Bolyai Research Grant BO/00723/22National Research, Development and Innovation Office 125377National Research, Development and Innovation Office 129266National Research, Development and Innovation Office 134863National Research, Development and Innovation Office 139269National Research, Development and Innovation Office 143549New National Excellence Programme of the Ministry of Human Capacities UNKP-22-3-SZTE-233New National Excellence Programme of the Ministry of Human Capacities UNKP-22-3-SZTE-278New National Excellence Programme of the Ministry of Human Capacities UNKP-22-4-SZTE-293New National Excellence Programme of the Ministry of Human Capacities UNKP-22-4-SZTE-296
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedColitis, UlcerativeAdministration, IntravenousGastrointestinal AgentsHumansHungaryAntibodies, Monoclonal, HumanizedGastrointestinal Agentsvedolizumab

Identifiers

PMID37352154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.